Liminatus Pharma Inc

Research Liminatus Pharma Inc (LIMN) on Bullrun: market cap USD 4.82M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerLIMN
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 4.82M
• Financial periodFY2025
• Net income-USD 10.21M
• Free cash flow-USD 9.98M

Valuation Snapshot

latest market cap is USD 4.82M.

About Liminatus Pharma Inc

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

Frequently asked questions

What is Liminatus Pharma Inc's market cap?

Liminatus Pharma Inc's market capitalization is USD 4.82M.

What does Liminatus Pharma Inc do?

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States.